U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H20FN3O4
Molecular Weight 361.3682
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OFLOXACIN

SMILES

CC1COc2c3c(cc(c2N4CCN(C)CC4)F)c(=O)c(cn13)C(=O)O

InChI

InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2688325 https://www.ncbi.nlm.nih.gov/pubmed/2688325

Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid, primary mechanism of action is inhibition of bacterial DNA gyrase. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Clinical trials to date have demonstrated the efficacy of ofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, and sexually transmitted diseases. Adverse effects to ofloxacin are usually mild and include gastrointestinal, central nervous system, and hypersensitivity reactions. Also available in solution for treatment of otic and ophthalmic bacterial infections.

CNS Activity

Curator's Comment:: Ofloxacin readily diffuses into CSF. There is a case report that ofloxacin could induce hallucinations. https://www.ncbi.nlm.nih.gov/pubmed/23716899

Originator

Sources: Umemura M. The Japanese Pharmaceutical Industry: Its Evolution and Current Challenges. Taylor & Francis 2011 pp. 208 ISBN 978-0-415-58766

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
OFLOXACIN, TABLET; ORAL

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae or Streptococcus pneumoniae. Community-acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. (See WARNINGS.) Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. (See WARNINGS.) Mixed Infections of the urethra and cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae. (See WARNINGS.) Acute pelvic inflammatory disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae. (See WARNINGS.) NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa . Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin. Therapy with ofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.

Launch Date

1.13944324E12
Curative
OFLOXACIN, SOLUTION/DROPS; OTIC

Approved Use

Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus,and Streptococcus pneumoniae.

Launch Date

1.19085125E12
Curative
OFLOXACIN, SOLUTION/DROPS; OPHTHALMIC

Approved Use

Ofloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Enterobacter cloacae, Haemophilus influenza, Proteus mirabilis, Pseudomonas aeruginosa) CORNEAL ULCERS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Pseudomonas aeruginosa, Serratia marcascens), Anaerobic species (Propionibacterium acnes)

Launch Date

1.36710717E12
Curative
OFLOXACIN, SOLUTION/DROPS; OPHTHALMIC

Approved Use

Ofloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Enterobacter cloacae, Haemophilus influenza, Proteus mirabilis, Pseudomonas aeruginosa) CORNEAL ULCERS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Pseudomonas aeruginosa, Serratia marcascens), Anaerobic species (Propionibacterium acnes)

Launch Date

1.36710717E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.5 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.4 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.6 μg/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41.2 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
43.5 μg × h/mL
400 mg 1 times / day steady-state, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14.1 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
21.2 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
31.4 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
61 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.5 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
68%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Other AEs: Traumatic injury, Headache...
Other AEs:
Traumatic injury (grade 1, 1 patient)
Headache (grade 1, 1 patient)
Insomnia (grade 2, 2 patients)
Malaise and fatigue (grade 1, 1 patient)
Nausea (grade 1, 2 patients)
Vomiting (grade 1, 4 patients)
Reaction skin (grade 1, 1 patient)
Pruritus (grade 1, 4 patients)
ALT (grade 1, 4 patients)
ALT (grade 2, 1patients)
Sources:
3 g single, intravenous
Overdose
Dose: 3 g
Route: intravenous
Route: single
Dose: 3 g
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Condition: acute left-upper-lobe pneumonia, asthma
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Disc. AE: CNS disorder (NOS)...
AEs leading to
discontinuation/dose reduction:
CNS disorder (NOS) (1 patient)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
venlafaxine(75 mg)
Sources:
unhealthy, 43 years
n = 1
Health Status: unhealthy
Condition: upper respiratory tract infection
Age Group: 43 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Orofacial dyskinesia...
AEs leading to
discontinuation/dose reduction:
Orofacial dyskinesia (1 patient)
Sources:
400 mg 1 times / day steady, oral (max)
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 81 years
n = 1
Health Status: unhealthy
Condition: urinary infections
Age Group: 81 years
Sex: F
Population Size: 1
Sources:
Other AEs: Psychiatric symptom NOS...
Other AEs:
Psychiatric symptom NOS (1 patient)
Sources:
300 mg 2 times / day steady, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
healthy, adult
n = 12
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 12
Sources:
400 mg single, oral
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, adult
n = 525
Health Status: healthy
Condition: induced first-trimester abortions
Age Group: adult
Sex: F
Population Size: 525
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache grade 1, 1 patient
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Malaise and fatigue grade 1, 1 patient
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Reaction skin grade 1, 1 patient
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Traumatic injury grade 1, 1 patient
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Nausea grade 1, 2 patients
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
ALT grade 1, 4 patients
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Pruritus grade 1, 4 patients
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Vomiting grade 1, 4 patients
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
ALT grade 2, 1patients
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
Insomnia grade 2, 2 patients
20 mg/kg 1 times / day steady, oral (max)
Recommended
Dose: 20 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 15 years
n = 55
Health Status: unhealthy
Condition: multidrug-resistant tuberculosis
Age Group: 0 - 15 years
Sex: M+F
Population Size: 55
Sources:
CNS disorder (NOS) 1 patient
Disc. AE
3 g single, intravenous
Overdose
Dose: 3 g
Route: intravenous
Route: single
Dose: 3 g
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Condition: acute left-upper-lobe pneumonia, asthma
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Orofacial dyskinesia 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
venlafaxine(75 mg)
Sources:
unhealthy, 43 years
n = 1
Health Status: unhealthy
Condition: upper respiratory tract infection
Age Group: 43 years
Sex: M
Population Size: 1
Sources:
Psychiatric symptom NOS 1 patient
400 mg 1 times / day steady, oral (max)
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 81 years
n = 1
Health Status: unhealthy
Condition: urinary infections
Age Group: 81 years
Sex: F
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
2001
Epidemiological analysis of Salmonella enterica serotype typhimurium from Hong Kong by ribotyping and pulsed-field gel electrophoresis.
2001
The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age.
2001
Antibiotic susceptibility, serum response and surface properties of Klebsiella species.
2001
Bacillus circulans endophthalmitis.
2001 Apr
On-column amperometric detection of ofloxacin and pasiniazid in urine by capillary electrophoresis with an improved fractured joint and small detection cell.
2001 Apr
Endocarditis due to Salmonella.
2001 Apr
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
2001 Apr
[Injectable quinolones].
2001 Apr
Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
2001 Apr
Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation.
2001 Apr
Comparative efficacy of new investigational agents against Helicobacter pylori.
2001 Apr
Urothelial mucosal concentration of levofloxacin administered before transurethral resection: Is the mucosal concentration predictable?
2001 Apr
[Use of levofloxacine in primary care for outbreaks in COPD].
2001 Apr 15
Stereoselective determination of ofloxacin and its metabolites in human urine by capillary electrophoresis using laser-induced fluorescence detection.
2001 Apr 15
A whole blood bactericidal assay for tuberculosis.
2001 Apr 15
Validation of an analytical procedure for the determination of the fluoroquinolone ofloxacin in chicken tissues.
2001 Apr 25
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
2001 Apr 27
[Recurrent abscesses in a renal transplant recipient].
2001 Feb
Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure.
2001 Feb
[Effect of subinhibitory levels of aminoglycosides and fluoroquinolines on hydrophobicity and motility of Serratia marcescens].
2001 Feb
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
2001 Feb
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.
2001 Jan
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].
2001 Jan-Feb
Effects of fluoroquinolones on the locomotor activity in rats.
2001 Mar
Clinical, histopathological and bacteriological investigations in two cases of relapse following ROM treatment.
2001 Mar
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
2001 Mar
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice.
2001 Mar
Treatment of tularemia with levofloxacin.
2001 Mar
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
2001 Mar
Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial.
2001 Mar
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
2001 Mar
Analysis of fluoroquinolone-mediated photosensitization of 2'-deoxyguanosine, calf thymus and cellular DNA: determination of type-I, type-II and triplet-triplet energy transfer mechanism contribution.
2001 Mar
[A case of suspected drug-induced ocular pemphigoid].
2001 Mar
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
2001 Mar
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
2001 Mar 12
What have we learned from pharmacokinetic and pharmacodynamic theories?
2001 Mar 15
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
2001 Mar 15
In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes.
2001 Mar-Apr
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women?
2001 May
Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial.
2001 May
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
2001 May
Antibiotic selective pressure and development of bacterial resistance.
2001 May
In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.
2001 May
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
2001 May
An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum.
2001 May
Zenker's diverticulum associated with multilevel cervical osteomyelitis.
2001 May 1
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
2001 May 15
Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas.
2001 May-Jun
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
2001 Spring
Patents

Sample Use Guides

OFLOXACIN TABLETS: the usual dose of ofloxacin tablets is 200 mg to 400 mg orally every 12 h. Ofloxacin Otic Solution 0.3% for otic use. Otitis Externa: Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear once daily for seven days (from 6 months to 13 years old patients). Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear once daily for seven days (for patients 13 years and older). Acute Otitis Media in Pediatric Patients with Tympanostomy Tubes: Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear twice daily for ten days. Chronic Suppurative Otitis Media with Perforated Tympanic Membranes: Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for fourteen days. Ofloxacin solution 0.3% for topical ophthalmic use. Bacterial conjunctivitis: Days 1 and 2 - Instill one to two drops every two to four hours in the affected eye(s); Days 3 through 7 - Instill one to two drops four times daily. Bacterial corneal ulcer: Days 1 and 2 - Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops; Days 3 through 7 to 9 - Instill one to two drops hourly, while awake; Days 7 to 9 through treatment completion - Instill one to two drops, four times daily.
Route of Administration: Other
In Vitro Use Guide
antibacterial activity of ofloxacin depends on strain: Enterobacteriaceae (MIC less than or equal to 0.12 mg/l), Vibrio cholerae (MIC less than or equal to 0.015 mg/l), V. parahaemolyticus (MIC less than or equal to 0.12 mg/l) Aeromonas hydrophila (MIC less than or equal to 0.03 mg/l), Staphylococcus spp. (MIC less than or equal to 1mg/l), beta-haemolytic Streptococcus spp. (MIC less than or equal to 2 mg/l), Corynebacterium diphtheriae (MIC less than or equal to 1 mg/l) and Cory. jeikeium (MIC less than or equal to 2 mg/l), alpha- and non-haemolytic Streptococcus spp., Str. pneumoniae and Listeria monocytogenes (MIC less than or equal to 4 mg/l for all species) and Str. faecalis (MIC less than or equal to 8 mg/l), Clostridium perfringens (MIC less than or equal to 1 mg/l), Cl. difficile (MIC less than or equal to 16 mg/l), Chlamydia trachomatis SA2f (MIC less than or equal to 0.5 mg/l).
Name Type Language
OFLOXACIN
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NSC-758178
Code English
OFLOXACIN [EP MONOGRAPH]
Common Name English
HOE-280
Code English
FLOXIN
Brand Name English
9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)(1,4)BENZOXAZINE-6-CARBOXYLIC ACID, DL-
Common Name English
OFLOXACIN [MART.]
Common Name English
7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (+/-)-
Common Name English
OFLOXACIN [WHO-DD]
Common Name English
OFLOXACIN [ORANGE BOOK]
Common Name English
OFLOXACIN [JAN]
Common Name English
J01MA01
Code English
OFLOXACIN [VANDF]
Common Name English
OFLOXACIN [USP-RS]
Common Name English
OFLOXACIN [USAN]
Common Name English
HOE 280
Code English
OCUFLOX
Brand Name English
OFLOXACIN [INN]
Common Name English
DL-8280
Code English
OFLOXACIN [USP MONOGRAPH]
Common Name English
OFLOXACIN [MI]
Common Name English
NSC-727071
Code English
Classification Tree Code System Code
WHO-ATC J01MA01
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-ATC J01RA09
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
NCI_THESAURUS C795
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-VATC QS01AE01
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
NDF-RT N0000007606
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-ATC S01AX11
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
LIVERTOX 704
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
NDF-RT N0000175937
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-VATC QS02AA16
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
FDA ORPHAN DRUG 56791
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-ATC S02AA16
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-ATC S01AE01
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
WHO-VATC QJ01MA01
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
Code System Code Type Description
CAS
82419-36-1
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
DRUG BANK
DB01165
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
FDA UNII
A4P49JAZ9H
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
EPA CompTox
82419-36-1
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
USP_CATALOG
1478108
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M8133
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY Merck Index
LACTMED
Ofloxacin
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL4
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
WIKIPEDIA
OFLOXACIN
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
RXCUI
7623
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
1981
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
INN
5322
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
HSDB
8030
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
MESH
D015242
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
EVMPD
SUB09422MIG
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
NCI_THESAURUS
C712
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY
PUBCHEM
4583
Created by admin on Fri Jun 25 21:03:53 UTC 2021 , Edited by admin on Fri Jun 25 21:03:53 UTC 2021
PRIMARY